Itonaga Masahiro, Ogura Takeshi, Isayama Hiroyuki, Takenaka Mamoru, Hijioka Susumu, Ishiwatari Hirotoshi, Ashida Reiko, Okuda Atsushi, Fujisawa Toshio, Minaga Kosuke, Takeshita Kotaro, Yamashita Yasunobu, Nishioka Nobu, Ishii Shigeto, Omoto Shunsuke, Ohtsuka Takao, Sofue Keitaro, Yasuda Ichiro, Shimokawa Toshio, Kitano Masayuki
Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Endoscopy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan.
Gastrointest Endosc. 2025 May;101(5):970-978. doi: 10.1016/j.gie.2024.11.005. Epub 2024 Nov 8.
EUS-guided hepaticogastrostomy (EUS-HGS) carries a risk of serious adverse events (AEs). A newly designed, partially covered laser-cut stent with antimigration anchoring hooks and a thin tapered tip (7.2F), called a Hook stent (Zeon Medical, Tokyo, Japan), has been developed to prevent serious AEs associated with EUS-HGS. The present prospective multicenter clinical trial evaluated the efficacy and safety of the Hook stent for EUS-HGS after failure of ERCP in patients with unresectable malignant biliary obstruction.
The primary endpoint was the rate of clinical success, and secondary endpoints were the rates of technical success, AEs, recurrent biliary obstruction (RBO), procedure success without using a tract dilation device, reintervention for RBO, time to RBO, and overall survival (OS).
Thirty-eight patients underwent EUS-HGS using the Hook stent. The technical and clinical success rates in patients undergoing EUS-HGS were 100% and 92.1%, respectively. The procedure success rate without using a tract dilation device was 94.7%. Four patients (10.5%) developed early AEs, but there were no severe AEs such as stent migration. RBO developed in 26.3% of patients. Reintervention for RBO had a 100% success rate. The median time to RBO was not reached, and the median OS was 191 days.
EUS-HGS using the Hook stent demonstrated a high clinical success rate, low rate of early AEs, and an acceptable stent patency. The Hook stent is safe and feasible for use in patients undergoing EUS-HGS. (Clinical trial registration number: jRCT2052210020.).
超声内镜引导下肝胃吻合术(EUS-HGS)存在严重不良事件(AE)风险。一种新设计的、带有防迁移锚定钩和细锥形尖端(7.2F)的部分覆膜激光切割支架,即Hook支架(日本东京Zeon Medical公司)已被研发出来,以预防与EUS-HGS相关的严重不良事件。本前瞻性多中心临床试验评估了Hook支架在不可切除恶性胆管梗阻患者内镜逆行胰胆管造影(ERCP)失败后用于EUS-HGS的有效性和安全性。
主要终点是临床成功率,次要终点是技术成功率、不良事件发生率、复发性胆管梗阻(RBO)发生率、不使用通道扩张装置的手术成功率、RBO再次干预率、RBO发生时间和总生存期(OS)。
38例患者使用Hook支架进行了EUS-HGS。接受EUS-HGS患者的技术成功率和临床成功率分别为100%和92.1%。不使用通道扩张装置的手术成功率为94.7%。4例患者(10.5%)发生早期不良事件,但未出现诸如支架迁移等严重不良事件。26.3%的患者发生RBO。RBO再次干预成功率为100%。未达到RBO的中位发生时间,中位总生存期为191天。
使用Hook支架的EUS-HGS显示出较高的临床成功率、较低的早期不良事件发生率和可接受的支架通畅率。Hook支架用于接受EUS-HGS的患者是安全可行的。(临床试验注册号:jRCT2052210020。)